Eli Lilly Acquires Akouos
Eli Lilly and Company has acquired Boston-based Akouos, Inc. The transaction is valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million. Akouos, Inc. is a precision genetic medicine company that is developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. Eli Lilly discovers, develops, manufactures and sells pharmaceutical products. Its products are sold in 125 countries. According to the LevinPro HC database, this acquisition is the 113th Biotechnology deal of the year. This compares with 100 Biotechnology transactions from January 1,... Read More »
AbbVie Acquires DJS Antibodies for $255 Million
AbbVie has acquired UK-based DJS Antibodies for $255 million. DJS Antibodies Ltd. is a biotechnology company dedicated to discovering and developing antibody medicines that target disease-causing proteins, such as G protein-coupled receptors. DJS’ lead program is DJS-002, a potential first-in-class lysophosphatidic acid receptor 1 antagonist antibody currently in investigational preclinical studies for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. DJS is backed by founding investors Oxford Science Enterprises and Johnson & Johnson Innovation Ltd., along with LifeArc, Sedgwick Yard and Amgen Ventures. AbbVie Inc. is a biopharmaceutical company that... Read More »
Pfizer Acquires Biohaven for $11.6 Billion in Its Biggest Deal Since 2016
On May 10, Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that they have entered into a definitive agreement under which Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, or approximately $11.6 billion. Pfizer had previously taken a 2.6% stake in Biohaven in November 2021 for $173 per share, or approximately $350 million. With this deal, Pfizer will compete in a crowded market for migraine treatments from other large drugmakers such as Eli Lilly and Amgen. The proposed transaction includes the acquisition of Biohaven’s calcitonin gene-related peptide programs including Rimegepant, which is approved in... Read More »KSL Biomedical Expands into Canada with Pulse Scientific Acquisition
KSL Biomedical Inc. has entered the Canadian market with the acquisition of Burlington, Ontario-based Pulse Scientific Inc., extending its international base for product distribution and laboratory sales, while positioning KSL for future acquisitions in the Burlington/Toronto area and beyond. Pulse Scientific is a privately-owned incorporation founded in 1992 that specializes in the supply of laboratory diagnostic tests for medical labs across Canada. Some examples of these tests include Syphillis, Rheumatoid Arthritis, drugs of abuse and microbiological products. KSL Biomedical is a translational medicine technology company based in Williamsville, New York. KSL has been growing rapidly... Read More »
AzurRz BioPharma Acquires First Wave Bio
AzurRz BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it has entered into a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at $229 million. H.C. Wainwright & Co. acted as advisor to AzurRx in connection with the acquisition. Founded in 2015, First Wave Bio, Inc. is a clinical-stage biotechnology company specializing in the development of novel, gut-targeted, small molecule therapies for the treatment of auto-immune inflammatory bowel diseases (IBD) and other serious conditions. AzurRx also announced that it... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
